The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Padcev-Keytruda is now the standard of care (SoC) in first-line mUC treatment due to the positive results of the Phase III EV-302 trial (NCT04223856), which found that the cancer-fighting duo ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

The bladder cancer market is projected to reach $16 billion across 8 major markets (8MM) by 2033, driven by new therapies and ...